Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5506209A · kind A · utility
32Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 26, 1994 |
| Grant date | Apr 9, 1996 |
| Priority date | — |
| Expiry date | May 26, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/832
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The infection of mammalian cells by RSV may be inhibited by native human .beta.-casein, a recombinant form of human .beta.-casein, and hydrolysates of both. The human .beta.-casein or hydrolysate may be contained in a liquid enteral nutritional product such as an infant formula. The enteral nutritional product may be used, for example, in the prevention and treatment of respiratory tract infection in infants. The human .beta.-casein or hydrolysate may also be administered as a throat spray or nasally using drops or a spray.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.